Skip to main content

Table 1 Demographic and outcome of 20 patients with Crohn’s disease referred for kidney biopsy after twelve-month treatments in detail

From: The pathological and outcome characteristics of renal lesions in Crohn’s disease

Patient

Sex

Age at kidney biopsy (yr)

Age at CD diagnosis (yr)

Renal pathology

CD treatment

Renal treatment

Outcome of CD

Outcome of proteinuria

Outcome of hematuria

1

M

45

43

IgA nephropathy

Thalidomide

RAS inhibitors, steroids intravenously

Remission

CR

CR

2

M

37

36

IgA nephropathy

Thalidomide

-

ND

ND

ND

3

F

17

15

IgA nephropathy

Methylprednisolone tablets, methotrexate

-

Remission

CR

PR

4

M

36

22

IgA nephropathy

Infliximab, azathioprine

-

Remission

CR

R

5

M

31

21

IgA nephropathy

Azathioprine, enteral nutrition

-

Remission

CR

CR

6

F

28

27

IgA nephropathy

Infliximab

Pozzi regimen

ND

ND

ND

7

F

16

18

Minimal change disease

Methylprednisolone tablets and azathioprine

Steroids intravenously

Remission

CR

CR

8

M

34

26

Minimal change disease

Enteral nutrition

RAS inhibitors

Response

CR

PR

9

F

19

18

Thin-basement-membrane nephropathy

Infliximab, azathioprine

-

Remission

CR

PR

10

F

38

37

IgA nephropathy

Thalidomide, enteral nutrition

-

Remission

CR

R

11

F

52

51

Acute interstitial nephritis

Thalidomide

Steroids intravenously

Remission

CR

CR

12

M

23

22

non-IgA mesangial proliferative nephritis

Infliximab, azathioprine

-

Response

CR

R

13

F

25

24

IgA nephropathy

Infliximab

Pozzi regimen

Remission

CR

CR

14

M

68

55

IgA nephropathy

Enteral nutrition

Prednisone acetate tablets, mycophenolate mofetil

Remission

R

PR

15

M

34

32

IgA nephropathy

Thalidomide

RAS inhibitors

Relapse

CR

CR

16

M

20

17

IgA nephropathy

Infliximab, azathioprine

Pozzi regimen

Remission

R

PR

17

F

65

42

Granulomatous interstitial nephritis

Infliximab

Prednisone acetate tablets

Remission

CR

CR

18

F

31

24

IgA nephropathy

Mesalamine, azathioprine

RAS inhibitors

ND

ND

ND

19

M

24

19

IgA nephropathy

Infliximab, azathioprine

RAS inhibitors

Remission

CR

PR

20

M

27

25

IgA nephropathy

Infliximab, azathioprine

-

Remission

CR

CR

  1. M Male, F Female, ND No data. “-” referred to without any treatments
  2. Outcome of CD: remission was defined as CDAI change from ≥ 150 or < 150 to < 150. Response was considered to be present if CDAI decreased by 70 or more but remained ≥ 150. Relapse was defined as CDAI change from < 150 to ≥ 150 or increased by 70 or more but remained ≥ 150
  3. Outcome of proteinuria or hematuria: complete remission (CR) was defined as urinalysis change from negative, trace or ≥ 1 + to negative or trace. Partial remission (PR) was considered to be present if urinalysis decreased more than one stage but remained ≥ 1 + . Relapse (R) was defined as urinalysis change from negative or trace to ≥ 1 + or increased more than one stage but remained ≥ 1 + 
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us